Review Article

Title: Safety profile and toxicity amelioration strategies of common adverse effects associated with anticancer medications

Abstract

More than half the cancer patients undergoing cancer chemotherapy develop adverse drug reactions (ADRs). Cancer chemotherapeutic agents have a lower risk-benefit ratio than other drug therapy treatments and kill cancerous as well as the normal rapidly dividing cells including bone marrow cells, gastrointestinal epithelium, hair follicles, etc. Their main ADRs are nausea and vomiting, mucositis, constipation, diarrhea, hematological toxicities, cardiac toxicity, alopecia, gonadal toxicity, pulmonary toxicity, neurotoxicity, nephrotoxicity, etc. The severity of the adverse effects may range from mild nausea to life-threatening neutropenia. Administering premedication and antidotes are very vital in these patients. Upon the occurrence of adverse effects, immediate steps should be taken to manage them. Though the ADRs due to anticancer medications are not avoidable, careful monitoring of the patients and modulating the drug schedules/dosages can help in minimizing them. Healthcare professionals should also develop strategies to minimize the occupational hazards associated with these drugs.

Keywords: Adverse drug reactions, Alopecia, Cancer chemotherapy, Hematological toxicity, teratogenicity, vomiting

Word count of abstract: 147

Main Text

Introduction

Cancer is considered to occur as a result of a disturbance in mechanisms that control cell proliferation and differentiation.[1] Radiotherapy, chemotherapy and surgery are the major treatment modalities available for the treatment of cancer.[2, 3] An ideal anticancer medicine should eradicate cancer cells without harming normal tissues. But the traditional existing medicines for cancer cause substantial toxicity and the use of these medicines must include careful consideration of benefits against toxicity.[4] In general, chemotherapy not only targets cancer cells but also other rapidly dividing normal cells of the human body.[5, 6] The damage to the normal cells produce various adverse effects which are also known as chemotherapy-induced adverse drug reactions. In this article, the authors discuss the various toxicities caused by anticancer medications and provide various methods for prevention, early diagnosis and management of these toxicities.

1. Nausea and Vomiting

One of the most common chemotherapy-induced adverse drug reactions (ADRs) are nausea and vomiting, and this can be broadly categorized as acute, delayed, or anticipatory.[7, 8] [Table 1]. Majority of the patients experience this ADR during chemotherapy. The severity of nausea and vomiting strongly depends on the type of chemotherapy regime and the dosage of individual drugs. The response of each individual to a given chemotherapy schedule varies.[8] The use of newer antiemetic agents has considerably reduced the incidence of nausea and vomiting though they may not prevent these.[9] Anticipatory nausea and vomiting are experienced by around 10- 44% of patients on chemotherapy.[10]

Pathophysiology

Different anticancer agents act at different sites and few of them act at more than one site.[11] These sites include the chemoreceptor trigger zone (CTZ), and the gastrointestinal tract. Vestibular and cortical mechanisms, altered taste and smell sensations may also contribute. The commonest mechanism is through the activation of CTZ. [12] Nausea and vomiting occurring within the first 24 hours of administration of chemotherapy are defined as acute, whereas those occurring after 24 are defined as delayed.[13] Anticipatory vomiting is a conditioned response typically occurring before the administration of chemotherapy.[13, 14]

Table 1. Emetogenic status of anticancer drugs[15]

Emetogenic status	Examples
Highly emetogenic drugs (causes vomiting in 75% or more of the cases)	Cisplatin, Cyclophosphamide, Cytosine arabinoside, Dacarbazine, Doxorubicin, Ifosfamide, Methotrexate, Mitomycin, Carmustine
Moderately emetogenic drugs (Causes vomiting in 50%-75% of the cases)	Carboplatin, Etoposide, Daunorubicin, Gemcitabine, Mitoxantrone, Topotecan, Cisplatin (< 40 mg/m^2), Doxorubicin (<60 mg/m^2), Cyclophosphamide (<1g)
Mildly emetogenic drugs (Causes vomiting in 25%-50% of the cases)	Asparaginase, Bleomycin, Busulfan, Chlorambucil, Cladribine, Docetaxel, Fludarabine, Fluorouracil, Hydroxyurea, Paclitaxel, Vincristine, Thiotepa, Melphalan

Management of chemotherapy-induced nausea and vomiting

For this purpose, patients are classified into three levels, level I (patients receiving mildly emetogenic agent), level II (patients receiving moderately emetogenic agent or patients receiving a

mildly emetogenic agent who has failed to respond to at least two of the level I drugs) and level III patients (patients receiving highly emetogenic agent, patients receiving 2 or more moderately emetogenic agents, patients who have failed a level II regimen).[16-18] [Table 2]

Table 2. Management of chemotherapy-induced nausea and vomiting

Levels	Management
Level I	1. Prochlorperazine 10 mg P.O. before chemotherapy followed by 10 mg P.O. 4-6th hourly after chemotherapy. 2. Dexamethasone 4 mg P.O. before chemotherapy 3. Lorazepam 1 mg P.O. 6th hourly.
Level II	1. Dolasetron 100 mg P.O. or IV. or Ondansetron 10mg IV or Granisetron 10mg/kg I.V. before chemotherapy 2. Dexamethasone 8 mg P.O. or 10mg I.V. before chemotherapy 3. Prochlorperazine 10 mg P.O. 4-6th hourly after chemotherapy. 4. Lorazepam 1mg P.O. 6th hourly.
Level III	1. Dolasetron 100mg I.V. or Ondansetron 32 mg I.V. or Granisetron 10mg/kg I.V. before chemotherapy 2. Dexamethasone 10-20mg I.V. before chemotherapy 3. Lorazepam 1mg P.O. before chemotherapy followed by 6th hourly after emotherapy 4. Metoclopramide 40mg P.O. 6th hourly x 4 days 5. Dexamethasone 4mg P.O. 6th hourly followed by 4mg 12th hourly for 1 day after chemotherapy

Corticosteroids are valuable antiemetics in preventing delayed emesis. Studies have shown an advantage for metoclopramide combined with steroids.[11, 17, 19] Lorazepam, is known to have some antiemetic effects.[11]

Delayed emesis: Two randomized studies, one with ondansetron and another with granisetron, indicated the usefulness of the serotonin antagonists for delayed emesis in patients receiving chemotherapy with agents of intermediary emetogenicity.[11, 20]

II. Gastrointestinal toxicity

Several chemotherapeutic drugs damage rapidly dividing cells of the gastrointestinal tract and cause mucositis and diarrhea.[21, 22]

1. **Mucositis**

   Oral mucositis is a known complication associated with cancer medicines.[23] Cells in the mouth are usually renewed every 7 to 14 days. Antimetabolites, hydroxyurea and procarbazine hydrochloride are commonly associated with this ADR.[24] Upon occurrence, patients experience epithelial hyperplasia, epithelial dysplasia and collagen and glandular degeneration.[25, 26] Poor nutritional status is known to worsen this condition.[27]

   Non-pharmacological interventions

   Non-pharmacological intervention includes consulting a dentist at least 2 weeks before starting chemotherapy, asking the dentist regarding brushing and flossing, use of soft toothbrush and gentle cleaning, brushing teeth and gums after every meal, avoiding irritating, acidic foods and juices, and spicy, salty, and coarse foods.[28]

Prophylactic measures and treatment

Chlorhexidine mouth wash, saline rinses, sodium bicarbonate rinses, betadine mouth wash, and ice are considered beneficial in preventing mucositis. Xylocaine, magnesium-based antacids, diphenhydramine, nystatin, and sucralfate, allopurinol, vitamin E and beta-carotene are also found to be beneficial.[28-30]

2. **Diarrhea**

Chemotherapy-induced diarrhea leads to alteration of patients' therapy, dose reductions and dose delays in patients and even complete termination of treatment.[31, 32] Drugs that induce diarrhea include 5-Fluorouracil, methotrexate, cytosine arabinose, capecitabine, and irinotecan. It is hard to forecast which patient may develop diarrhea. Management of diarrhea includes adequate fluid intake, oral rehydration preparations in mild to moderate diarrhea and intravenous fluid administration in case of severe fluid loss. Diarrhea can be controlled by Diphenoxylate+ Scopolamine 1 or 2 tabs. 3 or 4 times a day or Loperamide 2 capsules followed by 1 capsule after every loose stool (up to 8 capsules per day can be taken).

However, the stool should be investigated to rule out infective pathology especially during the nadir period (10-14 days after administration of chemotherapy). Infective diarrhea is managed with appropriate antibiotics or antimicrobials. For diarrhea caused due to irinotecan, atropine is given if diarrhea occurs within 24 hours of drug infusion. If diarrhea occurs after 24 hrs. it is managed by Loperamide 2mg once every 2hrs up to 12 hrs. after diarrhea subsides.[32, 33]

3. **Constipation**

Constipation is often an underestimated complication in patients with advanced cancer.[34] Constipation can be caused by vinca alkaloids like vincristine, vinblastine, vinorelbine and drugs used in supportive care such as narcotic analgesics and calcium-containing antacids. Vinca alkaloids cause constipation within 7 days from the day of administration.[32]

Management

Constipation can be managed by a diet high in bulk fiber, fresh fruits, vegetables, adequate fluid intake and laxatives such as senna or bisacodyl. Senokot is given as 2 tablets twice daily until regular bowel functioning followed by 1tab per day. Bisacodyl is given as 1 to 2 tablets per day if senna is ineffective. Lactulose 30 ml 2 to 3 times daily or milk of magnesia 30ml at bedtime can be added. Other alternatives include cisapride 10 to 20 mg 6^{th} hourly, magnesium citrate, bisacodyl suppository, and enema.[32]

III. Hematological toxicity

1. Toxicity to White Blood Cells (WBCs)

White blood cells (WBCs) are affected rapidly, due to their short life span resulting in neutropenia. The cells recover 3-4 weeks after chemotherapy. An absolute neutrophil count <1500/cmm will increase the risk of infections.[35, 36] To increase the WBC count, Granulocyte Colony Stimulating Factor (G-CSF) and Granulocyte-macrophage colony-stimulating factor (GM-CSF) are used frequently. G-CSF is administered subcutaneously at a dose of 300 mcg if the patient weighs less than 75 kg and 480 mcg if the patient's weight is 75kg or more. It causes adverse effects such as nausea, fever, bone pain which can be managed symptomatically. GM-CSF is administered intravenously or subcutaneously at a dose of 250 mcg/m^2. It causes adverse

effects such as fever, flushing, rigors and bone pain.[37] Febrile neutropenia is managed with appropriate drugs according to the treatment guidelines.[38, 39]

Preventive measures to reduce the threat of infection

Patients should be informed when their neutrophil count is low. The patient should be aware of the signs and symptoms of infection and report to the physician if he/she has any of the symptoms. When the neutrophil count is low, an infection can be prevented by avoiding crowds and persons with a cold, flu, or other infections. Keeping the body clean by bathing each day and washing hands after using the bathroom are recommended. Hands should be washed thoroughly before eating.

2. Toxicity to Platelets

Platelets are also affected due to chemotherapy resulting in thrombocytopenia. The usual time for the occurrence of thrombocytopenia is 10 to 21 days after the administration of chemotherapy.[40] Thrombocytopenia is managed with platelet transfusion when indicated. The usual indications for platelet transfusion include any evidence of bleeding, platelet count less than 10,000/cmm, and platelet count less than 20,000/cmm with fever.[40, 41]

3. Toxicity to Red Blood Cells (RBCs)

RBCs are also affected during chemotherapy. Anemia due to chemotherapy-induced myelosuppression typically happens 2 to 3 weeks subsequently the administration of chemotherapy. This toxicity can be managed by transfusion of blood and erythropoietin 40,000 units per week subcutaneously.[42, 43]

IV. Hair Loss

Body hair loss (alopecia) is common in chemotherapy and the degree of loss in patients is dependent both on antineoplastic agents used and dose. Long-term treatment may cause loss of pubic, axillary, and facial hair in addition to scalp hair. [44-46]

Alopecia due to cancer chemotherapy is not irreversible and re-growth of hair occurs 1- 2 months after treatment termination. Alterations in color and texture of hair may happen: hair shade may lighten or darken and often the hair curls as it regrows. Doxorubicin and cyclophosphamide are common anticancer drugs known to cause epilation (loss of hair). Alopecia may be expected with single-agent antibiotics, alkylating agents, nitrosoureas, and especially their combinations.[47, 48] Temporary vasoconstriction can reduce blood circulation in the scalp and can be beneficial in preventing hair loss by reducing access to the anticancer medicines to the hair follicles.[49]

V. Cardiac Toxicity

Anthracyclines, taxanes, cyclophosphamide, ifosfamide, vinca alkaloids, 5-fluorouracil, mitomycin-c, cisplatin, trastuzumab (Herceptin) are known to cause cardiac toxicity. Cardiomyopathy caused by the anthracyclines has three clinical presentations: acute, subacute, and late. The acute toxicity presents as myopericarditis, pericardial effusion, and myocardial dysfunction, sometimes leading to cardiac failure and occasionally death, within a few days of administration of the drug. The subacute presentation has an insidious onset and appears up to 200 days after the administration of the last dose. The late presentation occurs 5 or more years after completion of therapy.[50-53] Incidence of late abnormalities depends upon the cumulative dose of anthracycline received.[54-56]

Methods for preventing cardiomyopathy

Monitoring cardiac status, modification of drug delivery and use of cardioprotective agents are considered beneficial. Cardiac evaluation before anthracyclines and monitoring before each alternate treatment course till an aggregate dose of 300 mg/m^2 and reducing the peak dose of anthracycline are known to be beneficial.[56-58]

Cardioprotective agents such as vitamin E, ascorbic acid, n-acetyl-cysteine, coenzyme Q10 and amifostine may be useful in minimizing cardiotoxicity.[59] Cardiomyopathy caused by anthracyclines can be managed with inotropic support and afterload reduction, angiotensin-converting enzyme inhibitors and selective beta-receptor blockers, such as metoprolol and carvedilol.[60, 61]

VI. Neurotoxicity

Chemotherapy may have detrimental effects on either the central or peripheral nervous system. Drugs causing neurotoxicity include vinca alkaloids, cisplatin, oxaliplatin, cytosine arabinose, ifosfamide, 5-fluorouracil, methotrexate, paclitaxel, docetaxel, procarbazine, fludarabine, cladribine, pentostatin, etc.[61]

Vinca alkaloids are among the commonest group of drugs causing neurotoxicity. For vincristine, neurotoxicity is the main dose-limiting toxicity. The common signs caused by vincristine contain depression of the deep tendon reflexes, paresthesias of the distal extremities, motor dysfunction manifested as lower extremity weakness, cranial nerve involvement causing ophthalmoplegia and facial palsy, autonomic neuropathy causing orthostatic hypotension and erection/ejaculatory dysfunction.[62-64] Cisplatin and oxaliplatin-induced neuropathy can be manifested as sensory peripheral neuropathy, Lhermitte's sign, autonomic neuropathy, grand mal or focal seizures, encephalopathy, transient cortical blindness, retrobulbar neuritis, and retinal injury.[65] Manifestations of cytosine arabinose induced neuropathy include cerebellar dysfunction, seizures,

generalized encephalopathy, peripheral neuropathy, necrotizing leukoencephalopathy, spinal myelopathy, basal ganglia necrosis, and pseudobulbar palsy.[66] Neurotoxicity from methotrexate can manifest as meningeal irritation, transient paraparesis, or encephalopathy. When the drug is administered intrathecally (IT), it can cause headaches, nausea and vomiting, lethargy, nuchal rigidity, and other features of meningeal irritation.[67, 68]

Management

The mainstay of treatment involves the cessation of cancer chemotherapy and waiting for neurologic recovery. After cessation of therapy, neuropathy symptoms may continue for 3 to 4 years. Vitamin therapy may not be very effective. Intestinal dysfunction from autonomic neuropathy may be improved by metoclopramide therapy. Neurotoxic symptoms may last for months after cisplatin therapy is discontinued. Recovery from the neurologic effects usually occurs within a few days after discontinuing cytarabine therapy.[69]

VII. Nephrotoxicity: Cisplatin, cyclophosphamide, ifosfamide, methotrexate, mitomycin, carmustine, lomustine and streptozocin are known to cause renal toxicity.[70] The pathologic lesion of cisplatin nephrotoxicity is seen primarily in the proximal and distal tubules but may also involve the collecting ducts, whereas the glomeruli are unaffected. The hemolytic uremic syndrome has been reported in patients treated with cisplatin.[70, 71]

Management

Higher doses of cisplatin require aggressive hydration. Mannitol is also used to enhance diuresis, Amifostine demonstrated significant protection against cisplatin-induced nephrotoxicity.[72, 73] Twenty-four-hour creatinine clearance value less than 70 mL/min, particularly in patients 60 years

old or older is considered a contraindication for cisplatin therapy. [74] Treatment for mitomycin induced nephrotoxicity include hemodialysis and plasmapheresis.[75] Methotrexate-induced renal insufficiency can be largely prevented by hydration and urine alkalinization. Sequential hemodialysis and charcoal hemofiltration have been used as a treatment of acute nephrotoxicity from methotrexate.[71]

VIII. Hepatotoxicity: Several antitumor agents cause hepatic toxicity. The hepatotoxicity caused by chemotherapeutic drugs is manifested in three forms, which are chemical hepatitis, venoocclusive disease and chronic fibrosis. The antitumor drugs known to produce hepatotoxicity include l-asparaginase, carmustine, cytarabine, dactinomycin, etoposide, levamisole in combination with 5-fluorouracil, 6-mercaptopurine, and methotrexate in high doses, streptozocin, vincristine, busulfan and cyclophosphamide.[76, 77]

IX. Hypersensitivity reactions: Most antitumor agents can produce hypersensitivity reactions especially taxanes, which cause reactions severe enough to stop the treatment. Paclitaxel and Docetaxel produce hypersensitivity reactions including bronchospasm, angioedema, hypotension and pneumonitis.[78] Antianaphylaxis medication must be readily available and the patient should be observed after the drug is administered to avoid these reactions. Paclitaxel and docetaxel are administered throughout 1 to 3 hrs along with premedication using corticosteroids.[78, 79]

X. Gonadal dysfunction and teratogenicity: Infertility is an important problem for young adults treated with chemotherapy drugs.[80] In males, chemotherapy drugs result in loss of germinal cells leading to germinal aplasia. During the first 2 to 3 months of cytotoxic therapy, sperm counts may remain normal or be only moderately reduced. Some regimens cause azoospermia.[81, 82] When

sperm count recovers after cytotoxic therapy, fertility is generally restored. Drugs causing azoospermia include cisplatin, chlorambucil, cyclophosphamide, carmustine, and lomustine. [83-85] Methods to preserve fertility include semen cryopreservation, which is extremely important for men who want to preserve their fertility after cytotoxic treatment, and restoration of spermatogenesis is also possible with cryopreserved cells.[86, 87] In vitro fertilization (IVF), with artificial insemination, is important in achieving pregnancies from stored semen after the completion of cytotoxic therapy.[88] Ovulation may be temporarily stimulated by gonadotropin treatment and steroid hormone replacement therapy.[89]

XI. Cutaneous effects

Mucocutaneous surfaces are particularly susceptible to the adverse effects of antineoplastic agents, as they are composed of rapidly dividing cells.[90]

1. Nail complications: Nail involvement is dose-dependent, and may range from mild formation of multiple Beau's lines to severe onychomadesis, onycholysis and onychodystrophy. The big toe is the commonest nail to be affected. Nail pigmentation may be either diffuse or limited to the lunula or horizontal or vertical bands of pigmentation may occur. Anthracyclines (doxorubicin, daunorubicin) and taxanes (paclitaxel, docetaxel) commonly produce severe nail dystrophy and pigmentation in up to 40% of cases.[91]

2. Sweat gland abnormalities: Neutrophilic hidradenitis may occur in response to a range of antineoplastic agents, the commonest being cytarabine and bleomycin. Clinically erythematous papules, plaques and nodules are seen, mainly on acral areas. Syringosquamous metaplasia is closely related to neutrophilic hidradenitis and is due to the direct toxicity of antineoplastic agents on sweat ducts. Erythematous weals are seen, which resolve weeks after cessation of therapy. [92, 93]

3. Epidermal complications: The epidermal complications include toxic erythema and acral erythema.

a. Chemotherapy-induced toxic erythema: This is usually caused by busulfan, cytarabine, etoposide and methotrexate. There is a prodrome of tingling pain, followed by tender erythema and edema. Severe cases may resemble toxic epidermal necrolysis.[94, 95]

b. Chemotherapy-induced acral erythema: This is due to the concentration of drugs in sweat glands of palms and soles. It is most common with cytarabine and doxorubicin and develops in 1-3 weeks as sharply demarcated erythema of palms and soles.[96-98]

4. Keratoses: Multiple actinic and seborrheic keratoses may occur especially with fluorouracil and cytarabine.[99]

5. Hyperpigmentation: Bleomycin causes peculiar flagellate hyperpigmentation in 8-66% of cases.[100] Serpentine supravenous hyperpigmentation is caused by IV drugs like fluorouracil and vinorelbine. Daunorubicin causes polycyclic bands of scalp hyperpigmentation. Generalized hyperpigmentation is a common adverse effect of many cytotoxic agents, increased drug deposits due to increased blood flow, an increase in melanocyte-stimulating hormone (MSH) secretion and drug-induced depletion of tyrosinase inhibitors.[101, 102]

7. Photosensitivity: Phototoxic reactions simulating sunburns are common. Photoallergic reactions are seen as papulovesicular, mainly seen over photo exposed areas. Radiation enhancement reaction is a synergistic reaction between antineoplastic drugs (Vinca alkaloids) and radiation.[103]

8. Dermal adverse effects: These include local injury due to extravasation leading to chemical cellulitis manifesting as erythema, induration and pain at IV infusion sites, or even ulcers and severe necrosis attributable to drugs like doxorubicin. Cisplatin and Asparaginase are well known to cause urticaria and angioedema (65% incidence). Sclerotic dermal reactions mimicking morphea are well known with bleomycin, docetaxel and melphalan. Raynaud's phenomenon may occur secondary to bleomycin and cisplatin.[104]

XII. Carcinogenic effects:

Busulfan may also be leukemogenic.[105] Several cases of acute leukemia have been reported in patients who developed pancytopenia 5 to 8 years earlier secondary to the use of busulfan. In an evaluation of 439 children with acute lymphoblastic leukemia (ALL), an increased risk for the development of secondary myelodysplasia (MDS) or acute myeloid leukemia (AML) was demonstrated when mercaptopurine was administered in patients with low thiopurine methyltransferase (TPMT) activity or excessively high intracellular levels of thioguanine nucleotides and methylated mercaptopurine metabolites.[106-108]

XIII. Miscellaneous adverse effects: Some of the other adverse effects due to anticancer drugs are mentioned below.

1. Tumor lysis syndrome: This syndrome occurs from the rapid destruction of chemotherapy-sensitive cells resulting in the release of intracellular phosphate, urates, and other cell contents. Burkitt's and similar fast-growing lymphomas, and less frequently small cell lung cancer, breast cancer, and seminoma may show the syndrome.[109, 110] Administration of IV fluids, allopurinol and calcium gluconate are the usual methods of management.

2. Sepsis: In cancer patients undergoing combination chemotherapy, sepsis is a life-threatening condition.[111] A high incidence of streptococcal septicemia has been reported in patients with acute myelogenous leukemia following high-dose cytarabine therapy for remission induction or post-remission intensive consolidation. Prophylactic regimens, including cotrimoxazole, were ineffective in preventing this complication. More studies are required to confirm these findings. [112, 113]

3. Injection site extravasation:

Leakage of vincristine into adjacent tissue during intravenous administration may cause significant irritation; avoid extravasation. Dactinomycin is very corrosive, and extravasation for the duration of IV administration can result in cellulitis and injury to soft tissues and contracture of the arms.[114, 115] It can be managed by stopping the infusion, injecting hydrocortisone around the site and use of ice pack. It can be minimized by administering the drugs using central lines.[115]

Safe handling and toxicity of cancer chemotherapeutic agents to healthcare workers: Since cancer chemotherapeutic agents are a highly toxic group of drugs, they can also cause an occupational hazard to the health workers handling these medications. For example, health workers involved in preparing IV mixtures of cancer chemotherapeutic agents are likely to be exposed to these medications and can get affected. Often the chemotherapeutic agents may affect these health

workers through contaminated clothing, medical equipment, patient excreta, etc. The magnitude of the risk depends on the quantity of the exposure and the toxicity profile of the agent involved. These agents are known to enter the human body through direct skin contact, inhalation, skin surface, ingestion, or injection. Reconstituting powdered or lyophilized drugs can be another condition leading to exposure. Handling and disposal of unused chemotherapeutic agents can be also an associated issue. [116].

Conclusion

The prevalence of cancer is increasing. Chemotherapy is an important treatment modality. A thorough investigation of the health status of the patient should be done before starting chemotherapy. Appropriate premedication and antidotes can be of great help in minimizing the toxicity. On the occurrence of toxicity, immediate management measures should be taken. Though the toxicity profile of anticancer medications is unfavorable and some of the toxicities are not preventable, initiating appropriate steps can minimize these toxicities to a great extent. Apart from the adverse effects caused to the patients, these drugs can also cause serious hazards to the healthcare professions getting exposed to them. Hence all the healthcare professionals should take adequate preventive measures to minimize the exposure to the cancer chemotherapeutic agents as far as possible.

References

1. Cooper GM, Hausman RE. The development and causes of cancer. The cell: A molecular approach. 2000:725-66.
2. Arruebo M, Vilaboa N, Sáez-Gutierrez B, Lambea J, Tres A, Valladares M, González-Fernández Á. Assessment of the evolution of cancer treatment therapies. Cancers (Basel). 2011 Sep;3(3):3279-330.
3. Baskar R, Lee KA, Yeo R, Yeoh KW. Cancer and radiation therapy: current advances and future directions. Int J Med Sci. 2012;9(3):193.
4. Lind MJ. Principles of systemic anticancer therapy. Medicine. 2020 Jan 9.
5. Sak K. Chemotherapy and dietary phytochemical agents. Chemotherapy research and practice. 2012;282570-282570.
6. Chakraborty S, Rahman T. The difficulties in cancer treatment. Ecancermedicalscience. 2012;6.
7. Mustian KM, Darling TV, Janelsins MC, Jean-Pierre P, Roscoe JA, Morrow GR. Chemotherapy-induced nausea and vomiting. US Oncol. 2008;4(1):19.
8. Schnell FM. Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control. The oncologist. 2003;8(2):187-98.
9. Shaikh SI, Nagarekha D, Hegade G, Marutheesh M. Postoperative nausea and vomiting: A simple yet complex problem. Anesth Essays Res. 2016 Sep;10(3):388.
10. Roscoe JA, Morrow GR, Aapro MS, Molassiotis A, Olver I. Anticipatory nausea and vomiting. Supportive Care Cancer. 2011 Oct 1;19(10):1533-8.
11. Berger, A.M., J.L. Shuster, and J.H. Von Roenn, *Principles and practice of palliative care and supportive oncology*. 2007: Lippincott Williams & Wilkins.

12. Borison, H., *Anatomy and physiology of the chemoreceptor trigger zone and area postrema*, in *Nausea and vomiting: Mechanisms and treatment*. 1986, Springer.10-17.

13. Rapoport, B.L., *Delayed Chemotherapy-Induced Nausea and Vomiting: Pathogenesis, Incidence, and Current Management.* Front Pharmacol. 2017. 8:19-19.

14. Kamen, C., et al., *Anticipatory nausea and vomiting due to chemotherapy*. Eur J Pharmacol. 2014. 722:172-179.

15. Aoki, S., et al., *Difference in the emetic control among highly emetogenic chemotherapy regimens: Implementation for appropriate use of aprepitant.* Mol Clin Oncol. 2013. 1(1):41-46.

16. Chan, V.T. and W. Yeo, *Antiemetic therapy options for chemotherapy-induced nausea and vomiting in breast cancer patients.* Breast cancer (Dove Med Press), 2011. 3:151-160.

17. Rao, K.V. and A. Faso, *Chemotherapy-induced nausea and vomiting: optimizing prevention and management.* American health & drug benefits. 2012. 5(4):232.

18. Rashad, N. and O. Abdel-Rahman, *Differential clinical pharmacology of rolapitant in delayed chemotherapy-induced nausea and vomiting (CINV).* Drug Des Devel Ther, 2017. 11:947-954.

19. Gyawali, B., B.S. Poudyal, and M. Iddawela, *Cheaper options in the prevention of chemotherapy-induced nausea and vomiting.* J Glob Oncol. 2016. 2(3):145-153.

20. Griffin, C.E., et al., *Benzodiazepine pharmacology and central nervous system–mediated effects.* Ochsner J. 2013. 13(2):214-223.

21. Boussios, S., et al., *Systemic treatment-induced gastrointestinal toxicity: incidence, clinical presentation and management.* Ann Gastroenterol. 2012. 25(2):106-118.

22. Aprile, G., et al., *Treatment-related gastrointestinal toxicities and advanced colorectal or pancreatic cancer: A critical update.* World J Gastroenterol. 2015. 21(41):11793-11803.

23. Plevová, P., *Prevention and treatment of chemotherapy- and radiotherapy-induced oral mucositis: a review.* Oral Oncol, 1999. 35(5):453-70.

24. Saadeh, C.E., *Chemotherapy- and Radiotherapy-Induced Oral Mucositis: Review of Preventive Strategies and Treatment.* Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2005. 25(4):540-554.

25. Shirani, S., et al., *Epithelial dysplasia in oral cavity.* Iran J Med Sci. 2014. 39(5):406-417.

26. Ranganathan, K. and L. Kavitha, *Oral epithelial dysplasia: Classifications and clinical relevance in risk assessment of oral potentially malignant disorders.* J Oral Maxillofac Pathol. 2019. 23(1):19-27.

27. Ps, S.K., et al., *Radiation induced oral mucositis.* Indian J Palliat Care. 2009. 15(2):95-102.

28. Devi, S. and N. Singh, *Dental care during and after radiotherapy in head and neck cancer.* Natl J Maxillofac Surg. 2014. 5(2):117-125.

29. Mehdipour, M., et al., *A comparison between zinc sulfate and chlorhexidine gluconate mouthwashes in the prevention of chemotherapy-induced oral mucositis.* Daru. 2011. 19(1):71-73.

30. Köstler, W.J., et al., *Oral Mucositis Complicating Chemotherapy and/or Radiotherapy: Options for Prevention and Treatment.* CA Cancer J Clin. 2001. 51(5):290-315.

31. Stein, A., W. Voigt, and K. Jordan, *Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management.* Ther Adv Med Oncol. 2010. 2(1):51-63.

32. McQuade, R.M., et al., *Chemotherapy-Induced Constipation and Diarrhea: Pathophysiology, Current and Emerging Treatments.* Front Pharmacol. 2016. 7:414-414.

33. Anigilaje, E.A., *Management of Diarrhoeal Dehydration in Childhood: A Review for Clinicians in Developing Countries.* Front Pediatr. 2018. 6:28-28.

34. Mancini, I. and E. Bruera, *Constipation in advanced cancer patients.* Support Care Cancer. 1998. 6(4):356-364.

35. Lustberg, M.B., *Management of neutropenia in cancer patients.* Clin Adv Hematol Oncol. 2012. 10(12):825-826.

36. Newburger, P.E. and D.C. Dale, *Evaluation and management of patients with isolated neutropenia.* Semin Hematol. 2013. 50(3):198-206.

37. Moore, D.C., *Drug-Induced Neutropenia: A Focus on Rituximab-Induced Late-Onset Neutropenia.* P T. 2016. 41(12):765-768.

38. Lucas, A.J., J.L. Olin, and M.D. Coleman, *Management and Preventive Measures for Febrile Neutropenia.* P T. 2018. 43(4):228-232.

39. Lyman, G.H. and K.V.I. Rolston, *How we treat febrile neutropenia in patients receiving cancer chemotherapy.* J Oncol Pract. 2010. 6(3):149-152.

40. Slichter, S.J., et al., *Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients.* Blood. 2005. 105(10):4106-4114.

41. Izak, M. and J.B. Bussel, *Management of thrombocytopenia.* F1000Prime Rep. 2014. 6:45-45.

42. Bryer, E. and D. Henry, *Chemotherapy-induced anemia: etiology, pathophysiology, and implications for contemporary practice.* Inter Jour of Clin Trans Med. 2018. 6:21.

43. Shrestha S, Shakya R, Shrestha S, Shakya S. Adverse drug reaction due to cancer chemotherapy and its financial burden in different hospitals of Nepal. Int J Pharmacovigilance. 2017;2(1):1-7.

44. Balagula, Y., S.T. Rosen, and M.E. Lacouture, *The emergence of supportive oncodermatology: the study of dermatologic adverse events to cancer therapies.* J Am Acad Dermatol, 2011. 65(3):624-635.

45. Olsen, E.A., *Chemotherapy-induced alopecia: overview and methodology for characterizing hair changes and regrowth*, in *The MASCC Textbook of Cancer Supportive Care and Survivorship*. 2010, Springer. 381-386.

46. Groopman, J.E. and L.M. Itri, *Chemotherapy-induced anemia in adults: incidence and treatment.* J Natl Cancer Inst, 1999. 91(19):1616-34.

47. Haslam, I.S. and E. Smart, *Chemotherapy-Induced Hair Loss: The Use of Biomarkers for Predicting Alopecic Severity and Treatment Efficacy*. Biomark insights, 2019.14: 1177271919842180-1177271919842180.

48. Trüeb, R.M., *The difficult hair loss patient: A particular challenge.* Int J Trichol. 2013. 5(3):110.

49. Grevelman, E.G. and W.P. Breed, *Prevention of chemotherapy-induced hair loss by scalp cooling.* Ann Oncol, 2005. 16(3):352-8.

50. Floyd, J.D., et al., *Cardiotoxicity of Cancer Therapy.* J Clin Oncol. 2005. 23(30):7685-7696.

51. Gianni, L., E. Salvatorelli, and G. Minotti, *Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes.* Cardiovasc Toxicol, 2007. 7(2):67-71.

52. Madeddu, C., et al., *Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy.* J Cardiovasc Med (Hagerstown), 2016.17(1) Special issue on Cardiotoxicity from Antiblastic Drugs and Cardio protection: e12-e18.

53. Menna, P., E. Salvatorelli, and G. Minotti, *Cardiotoxicity of Antitumor Drugs.* Chem Res Toxicol. 2008. 21(5):978-989.

54. Sadurska, E., *Current Views on Anthracycline Cardiotoxicity in Childhood Cancer Survivors.* Pediatr Cardiol. 2015. 36(6):1112-1119.

55. Volkova, M. and R. Russell, *Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment.* Curr Cardiol Rev. 2011. 7(4):214-220.

56. Bansal, N., et al., *Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors.* Cardio-Oncology, 2019. 5(1):18.

57. Rahman, A.M., S.W. Yusuf, and M.S. Ewer, *Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation.* Int J Nanomedicine. 2007. 2(4):567-583.

58. McGowan, J.V., et al., *Anthracycline Chemotherapy and Cardiotoxicity.* Cardiovasc Drugs Ther. 2017. 31(1):63-75.

59. Akbay, E., et al., *Effects of N-acetyl cysteine, vitamin E and vitamin C on liver glutathione levels following amiodarone treatment in rats.* Kardiochir Torakochirurgia Pol. 2019. 16(2):88-92.

60. Di Filippo, S., *Beta-adrenergic receptor antagonists and chronic heart failure in children.* Ther Clin Risk Manag. 2007. 3(5):847-854.

61. Wu, A.H., *Management of patients with non-ischaemic cardiomyopathy.* Heart. 2007. 93(3):403-408.

62. Loghin, M.E. and A. Kleiman, *Medication-Induced Neurotoxicity in Critically Ill Cancer Patients*, in *Oncologic Critical Care*, J.L. Nates and K.J. Price, Editors. 2020, Springer International Publishing: Cham. 319-334.

63. Mora, E., et al., *Vincristine-induced peripheral neuropathy in pediatric cancer patients.* Am J Cancer Res. 2016. 6(11):2416-2430.

64. Starobova, H. and I. Vetter, *Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy.* Front Mol Neurosci. 2017. 10:174-174.

65. Staff, N.P., et al., *Chemotherapy-induced peripheral neuropathy: A current review.* Ann Neurol. 2017. 81(6):772-781.

66. Inaba, M., et al., *[Peripheral neuropathy, myelopathy, cerebellar ataxia, and subclinical optic neuropathy associated with copper deficiency occurring 23 years after total gastrectomy.* Rinsho Shinkeigaku. 2011. 51(6):412-6.

67. Cruz-Carreras, M.T., et al., *Methotrexate-induced leukoencephalopathy presenting as stroke in the emergency department.* Clin Case Rep. 2017. 5(10):1644-1648.

68. Bhojwani, D., et al., *Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia.* J Clin Oncol. 2014. 32(9):949-959.

69. de Caestecker, J.S., et al., *Evaluation of oral cisapride and metoclopramide in diabetic autonomic neuropathy: an eight-week double-blind crossover study.* Aliment Pharmacol Ther, 1989. 3(1):69-81.

70. Jia, J.B., et al., *Chemotherapy-related complications in the kidneys and collecting system: an imaging perspective.* Insights into imaging. 2015. 6(4):479-487.

71. Sharbaf, F.G., H. Farhangi, and F. Assadi, *Prevention of Chemotherapy-Induced Nephrotoxicity in Children with Cancer.* Int J Prev Med, 2017. 8:76.

72. Miller, R.P., et al., *Mechanisms of Cisplatin nephrotoxicity.* Toxins, 2010. 2(11):2490-2518.

73. Volarevic, V., et al., *Molecular mechanisms of cisplatin-induced nephrotoxicity: a balance on the knife edge between renoprotection and tumor toxicity.* J Biomed Sci. 2019. 26(1):25.

74. Ahn, M.-J., et al., *Clinical recommendations for defining platinum unsuitable head and neck cancer patient populations on chemoradiotherapy: a literature review.* Oral Oncol. 2016. 53:10-16.

75. Horie, S., et al., *Guidelines for treatment of renal injury during cancer chemotherapy 2016.* Clin Exp Nephrol. 2018. 22(1):210-244.

76. Sharma, A., et al., *Chemotherapy induced liver abnormalities: an imaging perspective.* Clin Mol Hepatol, 2014. 20(3): 317-326.

77. King, P.D. and M.C. Perry, *Hepatotoxicity of chemotherapy.* The oncologist, 2001. 6(2): 162-176.

78. Boulanger, J., et al., *Management of hypersensitivity to platinum- and taxane-based chemotherapy: cepo review and clinical recommendations.* Curr Oncol. 2014. 21(4):e630-e641.

79. Berger, M.J., et al., *Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction.* Support Care Cancer. 2015. 23(7):2019-2024.

80. Benedict, C., B. Thom, and J.F. Kelvin, *Fertility preservation and cancer: challenges for adolescent and young adult patients.* Curr Opin Support Palliat Care. 2016. 10(1):87-94.

81. Meistrich, M.L., *Effects of chemotherapy and radiotherapy on spermatogenesis in humans.* Fertil Steril. 2013. 100(5):1180-1186.

82. Wallach, E.E., M.D. Damewood, and L.B. Grochow, *Prospects for fertility after chemotherapy or radiation for neoplastic disease.* Fertil Steril. 1986. 45(4): 443-459.

83. Meistrich, M.L., *Male gonadal toxicity.* Pediatr Blood Cancer. 2009. 53(2):261-266.

84. Okada, K. and M. Fujisawa, *Recovery of Spermatogenesis Following Cancer Treatment with Cytotoxic Chemotherapy and Radiotherapy.* World J Mens Health. 2019. 37(2):166-174.

85. Chiba, K. and M. Fujisawa, *Fertility preservation in men with cancer.* Reprod Med Biol. 2014. 13(4):177-184.

86. Wyns, C., *Male fertility preservation before gonadotoxic therapies.* Facts Views Vis Obgyn. 2010. 2(2):88-108.

87. Hussein, A.A., N.D. Tran, and J.F. Smith, *Fertility preservation for boys and adolescents facing sterilizing medical therapy.* Transl Androl Urol. 2014. 3(4):382-390.

88. Zhang, A., et al., *Pregnancy and offspring outcomes after artificial insemination with donor sperm: A retrospective analysis of 1805 treatment cycles performed in Northwest China.* Medicine, 2019. 98(16):e14975-e14975.

89. Sullivan, S.D., P.M. Sarrel, and L.M. Nelson, *Hormone replacement therapy in young women with primary ovarian insufficiency and early menopause.* Fertil Steril. 2016. 106(7):1588-1599.

90. Biswal, S.G. and R.D. Mehta, *Cutaneous Adverse Reactions of Chemotherapy in Cancer Patients: A Clinicoepidemiological Study.* Indian J Dermatol. 2018. 63(1): 41-46.

91. Singal, A. and K. Bisherwal, *Disorders of nail in infants and children.* Indian J Dermatol. 2019. 20(2):101.

92. Beutner, K.R., C.H. Packman, and W. Markowitch, *Neutrophilic eccrine hidradenitis associated with Hodgkin's disease and chemotherapy. A case report.* Arch Dermatol, 1986. 122(7):809-11.

93. Brehler, R., et al., *Neutrophilic hidradenitis induced by chemotherapy involves eccrine and apocrine glands.* Am J Dermatopathol, 1997. 19(1):73-8.

94. Yang, C.H., et al., *Toxic epidermal necrolysis following combination of methotrexate and trimethoprim-sulfamethoxazole.* Int J Dermatol, 2000. 39(8):621-3.

95. Criado, P.R., *Adverse Drug Reactions.* Dermatology in Public Health Environments: A Comprehensive Textbook, 2016:519-576.

96. Ozmen, S., et al., *Probable cytarabine-induced acral erythema: report of 2 pediatric cases.* J Pediatr Hematol Oncol, 2013. 35(1):e11-3.

97. Farr, K.P. and A. Safwat, *Palmar-plantar erythrodysesthesia associated with chemotherapy and its treatment.* Case Rep Oncol. 2011. 4(1):229-235.

98. Burgdorf, W.H., W.A. Gilmore, and R.G. Ganick, *Peculiar acral erythema secondary to high-dose chemotherapy for acute myelogenous leukemia.* Ann Intern Med, 1982. 97(1):61-2.

99. Werbel, T. and P.R. Cohen, *Topical Application of 5-Fluorouracil Associated with Distant Seborrheic Dermatitis-like Eruption: Case Report and Review of Seborrheic Dermatitis Cutaneous Reactions after Systemic or Topical Treatment with 5-Fluorouracil.* Dermatol Ther (Heidelb). 2018. 8(3):495-501.

100. Suvirya, S., A. Agrawal, and A. Parihar, *5-Fluorouracil-induced bilateral persistent serpentine supravenous hyperpigmented eruption, bilateral mottling of palms and diffuse hyperpigmentation of soles.* BMJ Case Rep. 2014:bcr2014206793.

101. Geddes, E.R. and P.R. Cohen, *Antineoplastic agent-associated serpentine supravenous hyperpigmentation: superficial venous system hyperpigmentation following intravenous chemotherapy.* South Med J, 2010. 103(3):231-5.

102. Jamalpur, I., H.R. Mogili, and A. Koratala, *Serpentine supravenous hyperpigmentation.* Clin case rep. 2017. 5(9):1546-1547.

103. Gould, J.W., M.G. Mercurio, and C.A. Elmets, *Cutaneous photosensitivity diseases induced by exogenous agents.* J Am Acad Dermatol, 1995. 33(4):551-73

104. Kreidieh, F.Y., H.A. Moukadem, and N.S. El Saghir, *Overview, prevention and management of chemotherapy extravasation.* World J Clin Oncol. 2016. 7(1):87-97.

105. Fraser, M.C. and M.A. Tucker, *Second malignancies following cancer therapy.* Semin Oncol Nurs. 1989. 5(1):43-55.

106. Chevallier, P., et al., *Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial.* Haematologica. 2014. 99(9):1486-1491.

107. Jalaeikhoo, H., et al., *Acute Myeloid Leukemia as the Main Cause of Pancytopenia in Iranian Population.* Iran J Pathol. 2017. 12(3):265-271.

108. Kebriaei, P., et al., *Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia.* Biol Blood Marrow Transplant. 2018. 24(4):726-733.

109. Hsieh, P.-M., K.-C. Hung, and Y.-S. Chen, *Tumor lysis syndrome after transarterial chemoembolization of hepatocellular carcinoma: case reports and literature review.* World J Gastroenterol. 2009. 15(37):4726-4728.

110. Howard, S.C., D.P. Jones, and C.H. Pui, *The tumor lysis syndrome.* N Engl J Med, 2011. 364(19):1844-54.

111. Au E, Ang PT. Management of chemotherapy-induced neutropenic sepsis--combination of cephalosporin and aminoglycoside. Ann Acad Med Singapore.. 1993.22(3):319-22.

112. Gamis AS, Howells WB, DeSwarte-Wallace J, Feusner JH, Buckley JD, Woods WG. Alpha hemolytic streptococcal infection during intensive treatment for acute myeloid leukemia: a report from the Children's cancer group study CCG-2891. J Clin Oncol. 2000 May 9;18(9):1845-55.

113. Boztug H, Mühlegger N, Pötschger U, Attarbaschi A, Peters C, Mann G, Dworzak M. Antibiotic prophylaxis with teicoplanin on alternate days reduces rate of viridans sepsis and febrile neutropenia in pediatric patients with acute myeloid leukemia. Ann Hematol 2017 Jan 1;96(1):99-106.

114. Al-Benna S, O'Boyle C, Holley J. Extravasation injuries in adults. ISRN dermatol. 2013; 856541-856541.

115. Boschi R, Rostagno E. Extravasation of antineoplastic agents: prevention and treatments. Pediatr Rep. 2012;4(3).

116. The National Institute for Occupational Safety and Health Alert. P*reventing occupational exposures to antineoplastic and other hazardous drugs in health care settings*. The National Institute for Occupational Safety and Health, 2004 (2004-165). (Available from: http://www.escoglobal.com/resources/pdf/2004-165sum.pdf)